6628 Stock Overview
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Transcenta Holding Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.75 |
52 Week High | HK$6.20 |
52 Week Low | HK$1.17 |
Beta | -0.19 |
1 Month Change | -17.84% |
3 Month Change | -48.38% |
1 Year Change | -57.42% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -86.78% |
Recent News & Updates
Shareholder Returns
6628 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 9.4% | 5.7% | 3.6% |
1Y | -57.4% | -40.7% | -10.1% |
Return vs Industry: 6628 underperformed the Hong Kong Biotechs industry which returned -41.4% over the past year.
Return vs Market: 6628 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
6628 volatility | |
---|---|
6628 Average Weekly Movement | 12.7% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.6% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6628's share price has been volatile over the past 3 months.
Volatility Over Time: 6628's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 215 | Xueming Qian | www.transcenta.com |
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric cancer and is under Phase II clinical trial; TST005, a PD-L1/TGF-ß bi-functional antibody candidate which is under Phase Ia clinical trial for solid tumors, including certain lung cancers; TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing;TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST003, an antibody candidate targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells with mesenchymal phenotype; TST006, a bi-specific claudin 18.2/PD-L1 antibody; TST008, a tri-functional antibody combining a MASP2 antibody fused with a truncated transmembrane activator and CAML interactor protein; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors and is under Phase Ib/IIa clinical trials; and MSB2311, A humanized PD-L1 mAb Candidate for solid tumors and is under Phase Ib/IIa clinical trials.
Transcenta Holding Limited Fundamentals Summary
6628 fundamental statistics | |
---|---|
Market cap | HK$711.68m |
Earnings (TTM) | -HK$499.73m |
Revenue (TTM) | HK$58.17m |
12.2x
P/S Ratio-1.4x
P/E RatioIs 6628 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6628 income statement (TTM) | |
---|---|
Revenue | CN¥53.85m |
Cost of Revenue | CN¥39.45m |
Gross Profit | CN¥14.40m |
Other Expenses | CN¥476.97m |
Earnings | -CN¥462.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.14 |
Gross Margin | 26.74% |
Net Profit Margin | -859.01% |
Debt/Equity Ratio | 37.7% |
How did 6628 perform over the long term?
See historical performance and comparison